ID: ALA253717

Max Phase: Preclinical

Molecular Formula: C25H33ClN4

Molecular Weight: 389.57

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCN(CC)CCCC(C)Nc1c2ccccc2[n+](C)c2c1[nH]c1ccccc12.[Cl-]

Standard InChI:  InChI=1S/C25H32N4.ClH/c1-5-29(6-2)17-11-12-18(3)26-23-20-14-8-10-16-22(20)28(4)25-19-13-7-9-15-21(19)27-24(23)25;/h7-10,13-16,18H,5-6,11-12,17H2,1-4H3,(H,26,27);1H

Standard InChI Key:  KVDZSQVEWLLVGB-UHFFFAOYSA-N

Associated Targets(Human)

HUVEC 11049 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Plasmodium falciparum 966862 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Vero 26788 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Rhodesain 1463 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cathepsin B-like cysteine protease 88 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Trypanosoma brucei brucei 13300 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 389.57Molecular Weight (Monoisotopic): 389.2700AlogP: 5.22#Rotatable Bonds: 8
Polar Surface Area: 34.94Molecular Species: BASEHBA: 2HBD: 2
#RO5 Violations: 1HBA (Lipinski): 4HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 9.78CX Basic pKa: 10.47CX LogP: -0.59CX LogD: -2.65
Aromatic Rings: 4Heavy Atoms: 29QED Weighted: 0.41Np Likeness Score: -0.13

References

1. Lavrado J, Paulo A, Gut J, Rosenthal PJ, Moreira R..  (2008)  Cryptolepine analogues containing basic aminoalkyl side-chains at C-11: synthesis, antiplasmodial activity, and cytotoxicity.,  18  (4): [PMID:18207399] [10.1016/j.bmcl.2008.01.015]
2. Lavrado J, Reszka AP, Moreira R, Neidle S, Paulo A..  (2010)  C-11 diamino cryptolepine derivatives NSC748392, NSC748393, and NSC748394: anticancer profile and G-quadruplex stabilization.,  20  (23): [PMID:20952194] [10.1016/j.bmcl.2010.09.110]
3. Lavrado J, Cabal GG, Prudêncio M, Mota MM, Gut J, Rosenthal PJ, Díaz C, Guedes RC, dos Santos DJ, Bichenkova E, Douglas KT, Moreira R, Paulo A..  (2011)  Incorporation of basic side chains into cryptolepine scaffold: structure-antimalarial activity relationships and mechanistic studies.,  54  (3): [PMID:21207937] [10.1021/jm101383f]
4. Lavrado J, Mackey Z, Hansell E, McKerrow JH, Paulo A, Moreira R..  (2012)  Antitrypanosomal and cysteine protease inhibitory activities of alkyldiamine cryptolepine derivatives.,  22  (19): [PMID:22926067] [10.1016/j.bmcl.2012.07.104]

Source